UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 20, 2023
CATALENT, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36587 | 20-8737688 | ||
(State or other jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
14 Schoolhouse Road | ||
Somerset, New Jersey | 08873 | |
(Address of registrant’s principal executive office) | (Zip code) |
(732) 537-6200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbols(s) |
Name of each exchange on which registered | ||
Common Stock, $0.01 par value per share | CTLT | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
New Chief Financial Officer
On June 20, 2023, Catalent, Inc. (“Catalent” and, together with its subsidiaries, the “Company”), announced the appointment of Matti Masanovich as Senior Vice President and Chief Financial Officer, effective as of July 5, 2023. Mr. Masanovich will become a member of the Company’s Executive Leadership Team and serve as its principal financial officer. As of July 5, 2023, Ricky Hopson will cease to serve as Interim Chief Financial Officer and principal financial officer of the Company and, after supporting Mr. Masanovich in his transition, will return to a business leadership role at the Company.
Prior to joining the Company, Mr. Masanovich, age 51, served as Executive Vice President & Chief Financial Officer of Tenneco Automotive from August 2020 until November 2022, when Tenneco was acquired by funds managed by Apollo affiliates. Prior to that, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Superior Industries International from September 2018 until August 2020 and Senior Vice President & Chief Financial Officer of General Cable Corporation from November 2016 until July 2018. Earlier in his career, Mr. Masanovich had a series of roles of increasing responsibility in the finance functions of a variety of companies in the automotive industry and began his career with PriceWaterhouseCoopers LLP. He has a Bachelor of Commerce, Finance & Accounting and M.B.A. degrees from the University of Windsor and is a Chartered Accountant in Canada.
The Company confirms, as required by the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), that (1) there is no arrangement or understanding between Mr. Masanovich and any other person pursuant to which he was elected as an officer of the company, (2) there is no family relationship between Mr. Masanovich and any director or executive officer of the Company, and (3) there is no direct or indirect transaction between Mr. Masanovich and the Company that would require disclosure under Item 404(a) of Regulation S-K under the Exchange Act.
The Company has entered into an offer letter, dated June 15, 2023, with Mr. Masanovich (the “Offer Letter”), as well as a severance agreement which provides for terms applicable to all senior executives other than Catalent’s Chief Executive Officer and is substantially in the form provided as Exhibit 10.3 to the Annual Report on Form 10-K filed September 17, 2010 by Catalent’s wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Form Severance Agreement”). The terms of the Offer Letter and the Form Severance Agreement are summarized as follows:
Base Salary. Mr. Masanovich’s annual base salary will be $800,000.
Bonus. Mr. Masanovich will be eligible for a cash bonus under the terms of the Company’s Management Incentive Plan, the incentive-based annual cash bonus plan for the Company’s executives, with a target amount of $640,000, beginning with the Company’s 2024 fiscal year, pro-rated based on his hire date.
Long-Term Incentive Award. Mr. Masanovich will be eligible to participate in Catalent’s Long-Term Incentive Plan with an initial annual grant target of $5,000,000 for the Company’s 2024 fiscal year, and in future years, an annual grant target of $2,500,000, allocated in the same manner as applies to all members of the Company’s Executive Leadership Team, under Catalent’s 2018 Omnibus Incentive Plan, a copy of which is provided as Exhibit 10.1 to Catalent’s Quarterly Report on Form 10-Q filed November 6, 2018.
Termination of Employment. Under his severance agreement, if Mr. Masanovich is involuntarily terminated for any reason other than “Cause” (as defined in that agreement), leaves his employment due to death or disability, or terminates his employment for “Good Reason,” as defined in that agreement, he would be entitled to (i) a severance payment equal to the sum of annual base salary and target annual bonus, payable in equal installments over the one-year period following the date of termination; and (ii) continued participation for up to one year in the Company’s group health plans (to the extent he was receiving such coverage as of the termination date), at the same premium rates as may be charged from time to time to the Company’s U.S. employees generally.
The foregoing descriptions of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the Form Severance Agreement are qualified in their entirety by reference to the Offer Letter and the Form Severance Agreement, with the full text of each item incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On June 20, 2023, the Company issued a press release announcing Catalent’s appointment of Matti Masanovich as Senior Vice President and Chief Executive Officer. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
As provided in General Instruction B.2 of Form 8-K, Exhibit 99.1 and the information contained in this Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, nor shall they be deemed to be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
Description | |
10.1 | Offer letter, dated June 15, 2023, between Matti Masanovich and the Company. | |
99.1 | Press release, dated June 20, 2023, issued by the Company. | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Catalent, Inc. | ||
(Registrant) | ||
By: | /s/ STEVEN L. FASMAN | |
Steven L. Fasman | ||
Executive Vice President, Chief Administrative Officer | ||
Date: June 20, 2023 |
Exhibit 10.1
June 15, 2023
Matti Masanovich
[Address on file with Company]
Dear Matti:
Congratulations on this offer to join our team! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalents expertise and capabilities and its collaborations with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help us develop, supply, and deliver billions of doses of life-enhancing products. We take great pride in hiring professionals like you, who have talent, drive, and commitment. We cant wait to have you join us as we work to advance new medicines for the benefit of patients around the world. Were confident that you will find your career with Catalent to be filled with opportunities, new challenges, and meaningful work. Attached is important information about our organization and your individual position, rewards, and benefits.
The major provisions of your offer, which is subject to the approval of Catalents Board of Directors or its Compensation and Leadership Committee (CLC), are:
Position: Your position will be Senior Vice President and Chief Financial Officer, reporting directly to Alessandro Maselli, President & CEO. You will also be a member of Catalents Executive Leadership Team (ELT). The situs of this position is our corporate headquarters in Somerset, New Jersey. While we acknowledge that your primary residence will remain in Fort Lauderdale, Florida, we will expect you to spend at least 50% of your time either in our Somerset offices or traveling on Catalent business.
Compensation: Your bi-weekly base rate of pay will be $30,769 (annualized to $800,000). Catalent employees are paid every other Friday, one week in arrears (one week behind the most current workweek youve completed).
Performance: Performance and merit-based compensation are reviewed as part of an annual process that generally takes place starting during the last quarter of a fiscal year and ending during the first quarter of the following fiscal year. Assuming that your start date will be on or about July 5, 2023, your first compensation review will likely occur in the annual process for the fiscal year beginning July 1, 2024.
Rewards: Catalent is pleased to offer a comprehensive, competitive compensation program that rewards talented employees for their performance. Effective on your first day of employment, you will be eligible for our health, life, disability, and 401(k) retirement savings plans, as well as all other plans and programs generally available to our U.S. employees. You will receive more information on these benefits during your new hire orientation session. In addition, you will receive or be eligible to participate in the following:
| You are eligible to participate in Catalents short-term incentive plan, which we call the Management Incentive Plan (MIP). Your annual incentive target will be $640,000. You will be eligible for a MIP bonus beginning in our 2024 fiscal year (July 1, 2023 June 30, 2024), pro-rated based on your hire date. Annual bonus payments are determined based upon the achievement of specific company and personal objectives and are not guaranteed. In order to receive your MIP payment, you must be actively employed at the time of payout. Please refer to the MIP summary document for further details. |
Page 1 of 4
| In recognition of your leadership position, you will be recommended to receive an initial Long-Term Incentive Plan (LTIP) annual grant equal to $5,000,000. Since LTIP grants have equity components, your grant is subject to the approval of the CLC. The initial grant date will be your hire date. In future years, your LTIP target will be $2,500,000. LTIP grants are made during the first quarter of each fiscal year in accordance with Catalents standard equity grant cycle. The complete terms and conditions of the LTIP, including the equity components and related award agreements, will be provided to you shortly after your hire date and are conditioned on, among other things, your acceptance of certain restrictive covenants. |
| As a member of the ELT, you will be eligible to participate in Catalents Deferred Compensation Plan, which enables you to save over the IRS limits in the qualified 401(k) plan. Complete details on the features of this plan and how to enroll will be mailed to your home following your hire date. You will also be eligible for all other benefits generally made available to members of the ELT, including: |
| Financial Planning: Each calendar year, as a member of the ELT, you are eligible for financial planning either by using AYCO (the financial planning unit of Goldman Sachs) or a financial planner of your choice. If you use a financial planner of your choice, your maximum reimbursement per annum is $15,000, which will be considered taxable income and taxed accordingly. More details on financial planning will be provided after your hire date. |
Paid Time Off: Upon joining Catalent, you will receive eight (8) paid company holidays (New Years Day, MLK Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and the day following, and Christmas Day). In addition:
| You will be eligible to receive 208 hours (26 days) of PTO per calendar year, pro-rated in your first year based on the number of months you are employed. Future increases to PTO entitlement will be in accordance with Catalents prevailing Company PTO policy. PTO includes vacation, sick, and personal days. Carryover of unused PTO is allowed as and to the extent set forth in Catalents PTO policy. |
Start Date: Your first day of employment will be on July 5, 2023, subject to the satisfactory completion of a background check and drug screening test.
Severance: You will receive a separate severance letter agreement, which entitles you to a severance benefit equal to your annual base salary plus MIP target bonus, subject to the terms of the letter agreement.
Stock Ownership: As Senior Vice President and Chief Financial Officer, you will be subject to Catalents Executive Stock Ownership Guidelines. These are available from Human Resources.
Reimbursement of legal fees: Within 60 days of your hire date, Catalent will reimburse you for legal fees you may have incurred in conjunction with the acceptance of this offer, up to $2,000, upon submission of an expense reimbursement request subject to our usual requirements.
Offer Requirements: Consistent with our policies for all Catalent personnel and the special considerations of our industry, this offer is contingent upon the satisfactory completion of a drug screen and background check, including reference checks.
| The company-paid drug screen must be completed within 30 calendar days prior to your start date, with acceptable results. After acceptance of this offer, a chain of custody form, required for your drug screen, will be sent to you via e-mail by our vendor with information on how to complete the drug screen. The e-mail will also contain contact information for the nearest testing facility to your home address. Be sure to bring a printed copy of the e-mail along with a government-issued photo ID to the facility in order to process your drug screen. |
Page 2 of 4
| A background check, including reference checks, must be complete prior to your start of employment, with satisfactory results. You will be receiving an e-mail from our vendor with information on how to complete the necessary documentation to initiate the required checks and to provide your authorization. |
| On your first day of employment, you will receive and will be asked to sign the Catalent Pharma Solutions Confidentiality Agreement. |
| The Immigration Reform and Control Act of 1986 requires employers to verify the employment eligibility and identity of all new employees. In accordance with this Act, please bring the appropriate identifying documents with you on your first day of employment. An electronic copy of the I-9 form, including a list of accepted documentation for proof of work authorization, will be sent to you after you pass all pre-hire contingencies. |
| Catalent does not hire employees for the purpose of acquiring their former employers trade secrets, intellectual property, or other confidential or proprietary information. In that regard, Catalent expects you to honor your legal obligations to your former employer(s), and you are not permitted to utilize any confidential or proprietary information of your former employer(s) in order to conduct business on behalf of Catalent under any circumstances. |
| Your signature accepting this offer of employment is also your confirmation that you are either not a party to a non-competition or non-solicitation agreement that implicates your duties at Catalent or are a party to such an agreement and will honor your legal obligations to your current (and/or former) employer. If you believe that you cannot perform effectively for Catalent under any lawful and applicable restriction, you must promptly inform Catalent of that fact. Further, in the event any legal action is taken by your former employer as a result of your employment by Catalent, Catalent will have no legal obligation to pay or reimburse you for your legal fees, representation, or damages associated with that legal action. Catalent will take whatever steps it deems appropriate under those circumstances. |
Term: Employment with Catalent is not for any definite period of time and is terminable, with or without notice or reason, at the will of either you or the company. There shall be no contract of employment, express or implied.
Ethics: As a company founded on a core set of values, you will be provided with Catalents Standards of Business Conduct and will be required to sign a letter of compliance at the commencement of employment and from time to time thereafter.
Page 3 of 4
Please signify your acceptance of this offer of employment by scanning/emailing a signed/dated copy of this offer letter to my attention.
If you have any question, please feel free to call me at ###-###-####.
Sincerely yours,
/s/ Ricardo Pravda
Ricardo Pravda
I accept the above offer of employment:
/s/ Matti Masanovich |
June 17, 2023 | |||
Matti Masanovich | Date |
Page 4 of 4
Exhibit 99.1
Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer
SOMERSET, N.J., June 20, 2023 Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023.
Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by Apollo. Previously he was Chief Financial Officer at Superior Industries International and General Cable Corporation.
Matti is a proven finance leader whose deep experience growing and driving profitability at publicly traded, complex global manufacturing companies is ideally suited to help Catalent reach its next level of performance, including enhanced profitability and value-creation for shareholders, said Alessandro Maselli, President and Chief Executive Officer of Catalent. He brings significant expertise and a highly strategic approach that I am confident will make him an invaluable addition to Catalents executive leadership team as we continue to seize opportunities in the CDMO space.
Earlier in his career, Mr. Masanovich held finance leadership roles of increasing responsibility in a number of companies in the automotive industry, where he demonstrated a strong history of improvement and profitability and operating efficiency. Mr. Masanovich began his career with PricewaterhouseCoopers LLP. He has Bachelor of Commerce, Finance & Accounting and M.B.A. degrees from the University of Windsor and is a Chartered Accountant in Canada.
Catalent is a dynamic company that operates in a critical, fast-growing sector that has a meaningful impact on helping people live longer, healthier lives. I am impressed with their portfolio of solutions and feel the company has the right capabilities to serve that market, and I am excited to work with Catalents talented team to create value for its customers, patients, and shareholders, said Mr. Masanovich.
Mr. Masanovich will have responsibility for all aspects of Catalents global financial operations, including financial planning and analysis, controllership, public reporting and investor relations, capital markets activities, bill payment and collection, tax, and treasury. He will also be a member of Catalents executive leadership team, the highest level of company management.
About Catalent
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized
medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalents expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual future events, results or achievements to be materially different from Catalents expectations and projections expressed or implied by the forward-looking statements. Important factors include, but are not limited to, those discussed under the caption Risk Factors in Catalents Annual Report on Form 10-K for the year ended June 30, 2022 (as amended), Catalents Quarterly Report on Form 10-Q for the three and nine months ended March 31, 2023, and Catalents other filings with the SEC. Forward-looking statements speak only as of the date of this press release and are based on information available to Catalent as of the date of this press release, and Catalent assumes no obligation to update such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com
Media Contact:
Chris Halling
+44 (0)7580 041073
media@catalent.com